CorriX

Excellence of
the CorriX

CorriX has demonstrated its safety and efficacy through non-clinical and human study.
It was introduced as “NGP (Next-Generation Probiotics) on well-known scientific review journal ‘Nature’ based on its cancer surveillance function.

Safety

  • In vitro

    CorriX has been confirmed to show the absence of antibiotic resistance and toxic genes
    in vitro.

  • In vivo

    CorriX has been confirmed to cause no adverse effects during 90-day repeated administration in vivo. It also showed no abnormalities in the reverse mutation test and chromosomal aberration test.

  • Human study

    The safety of CorriX has been proven in human study for consumption by healthy adults.

[Appl Environ Microbiol. 2012 Jan; 78(2): 528–535.]
Strain identification and
safety Verification - In vitro
  • Strain Identification and Safety Verification
  • Confirmation of the Absence of
    Antibiotic Resistance and Toxic Genes
[Regulatory Toxicology and Pharmacology 62 (2012) 336–346]
Safety Verification - In vivo
  • Safety Verification in Animal Studies
  • No Adverse Effects Observed in Mutation Tests, Chromosomal Aberration Tests, and 90-Day Repeated Dose Studies
[Beneficial Microbes, June 2012; 3(2): 99-111]
Safety Verification - Human study
  • Human Safety Verification
  • No Adverse Effects Observed During Consumption by Healthy adults